The Million Hearts initiative launched in 2012 set a lofty goal of preventing 1 million cardiovascular deaths in 5 years, but did not quite achieve that target. According to the program’s executive director, Janet Wright, MD, FACC, Million Hearts will continue to make progress in part due to the solid foundations it has formed in the initial stage.
The Million Hearts initiative launched in 2012 set a lofty goal of preventing 1 million cardiovascular deaths in 5 years, but did not quite achieve that target. According to the program’s executive director, Janet Wright, MD, FACC, Million Hearts will continue to make progress in part due to the solid foundations it has formed in the initial stage.
Transcript (slightly modified)
What are the goals of the Million Hearts initiative?
The aim of Million Hearts 2022 is exactly the aim of Million Hearts 1.0, and that is to prevent a million cardiovascular events over a 5-year time frame. We made progress in our first 5 years, but I don’t think we’re going to get to a million. The projected numbers indicate we’ll probably fall short of that.
But we’ve amassed extraordinary partnerships and instituted policies. We’ve seen programs and pilots be launched during the first 5 years that will extend well beyond and will continue to make improvements in cardiovascular health and cardiovascular care.
What did your team learn from the obstacles the initiative has encountered in the first stage?
What we learned in 5 years of working is that change is hard, and it takes time. We’re frustrated by the slow pace of that change, but we did see progress. Over the 5 years of 2012 to 2016, we saw blood pressure control improve by about 1% per year. In order to deliver a million events, our model showed that we needed improvement at 5% per year.
The good news is that we saw, we met, and we learned from high performers in blood pressure control around the country over that 5 years’ time, so we know that high performance is possible, and many of those lessons turned into success stories that are available on our website.
With cholesterol, we saw an improvement a little bit greater, and we’re going to get close to the population level target that we set, but we’re not going to get all the way there. We did see a target reached in terms of smoking cessation, and it’s due to collective efforts around the country. In fact, 7 million people had stopped smoking over the period of Million Hearts.
We’ve seen a little bit of an improvement in aspirin, but we didn’t make any headway at all in sodium reduction. All of those factors needed to occur together in order to prevent a million.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More